Trial Profile
Safety and efficacy of daclatasvir and asunaprevir combination therapy in patients with genotype 1b chronic hepatitis C patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018